CN113214327B - 一种具有抗肿瘤活性的功能分子、制备方法及其应用 - Google Patents
一种具有抗肿瘤活性的功能分子、制备方法及其应用 Download PDFInfo
- Publication number
- CN113214327B CN113214327B CN202110449534.2A CN202110449534A CN113214327B CN 113214327 B CN113214327 B CN 113214327B CN 202110449534 A CN202110449534 A CN 202110449534A CN 113214327 B CN113214327 B CN 113214327B
- Authority
- CN
- China
- Prior art keywords
- functional molecule
- tumor activity
- activity according
- pinacol ester
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical compound [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims abstract description 13
- GZZBZWITJNATOD-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CO)C=C1 GZZBZWITJNATOD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000005886 esterification reaction Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 7
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000010898 silica gel chromatography Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 16
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 230000002378 acidificating effect Effects 0.000 abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 5
- 125000004185 ester group Chemical group 0.000 abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 6
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- MDCWDBMBZLORER-UHFFFAOYSA-N triphenyl borate Chemical compound C=1C=CC=CC=1OB(OC=1C=CC=CC=1)OC1=CC=CC=C1 MDCWDBMBZLORER-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic System
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110449534.2A CN113214327B (zh) | 2021-04-25 | 2021-04-25 | 一种具有抗肿瘤活性的功能分子、制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110449534.2A CN113214327B (zh) | 2021-04-25 | 2021-04-25 | 一种具有抗肿瘤活性的功能分子、制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113214327A CN113214327A (zh) | 2021-08-06 |
CN113214327B true CN113214327B (zh) | 2023-12-01 |
Family
ID=77088887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110449534.2A Active CN113214327B (zh) | 2021-04-25 | 2021-04-25 | 一种具有抗肿瘤活性的功能分子、制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113214327B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107827936A (zh) * | 2017-11-23 | 2018-03-23 | 南京工业大学 | 二茂铁硒醚衍生物的制备及其应用 |
-
2021
- 2021-04-25 CN CN202110449534.2A patent/CN113214327B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107827936A (zh) * | 2017-11-23 | 2018-03-23 | 南京工业大学 | 二茂铁硒醚衍生物的制备及其应用 |
Non-Patent Citations (2)
Title |
---|
基于β-环糊精改性的水溶性苝酰亚胺 的合成及其pH响应性研究;杨靖等;《陕西科技大学学报》;第38卷(第1期);第81-87页 * |
环糊精超分子聚合物在药物/基因递送载体领域的研究进展;刘彩萍等;《化学通报》;第81卷(第4期);第326-383页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113214327A (zh) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110478318B (zh) | 一种芬顿试剂和阿霉素共转运靶向纳米载体及其制备方法 | |
CN113214327B (zh) | 一种具有抗肿瘤活性的功能分子、制备方法及其应用 | |
CN111166882B (zh) | 酞菁-rgd多肽-氧化石墨烯复合纳米材料及其制备方法与应用 | |
Qiu et al. | Design, synthesis and evaluation of dual-targeting prodrug co-modified by organic amine and L-ascorbic acid for CNS delivery | |
CN114907427B (zh) | 一种槲皮素的葡萄糖苷衍生物及其制备方法和应用 | |
CN114057803A (zh) | 一种具有抗肿瘤活性的功能分子、制备方法及其应用 | |
CN108610460B (zh) | 一种活性氧刺激响应型纳米凝胶药物载体及其制备方法和应用 | |
CN111635464B (zh) | 一种5-氨基酮戊酸葡聚糖酯的制备方法 | |
CN108864148B (zh) | 一种雷帕霉素-40-苹果酸钠盐及其制备方法和应用 | |
CN1022562C (zh) | 一种消瘤药——甲硝唑氨酸的合成方法 | |
KR100441270B1 (ko) | 수용성 유리 아민 키토산의 제조방법 | |
CN111592484A (zh) | 一种5-氨基酮戊酸盐酸盐中间体的制备方法 | |
KR20120092467A (ko) | 효소를 이용한 6-o-시나밀-l-아스코르브산 유도체의 합성방법 | |
CN100374429C (zh) | 以10-去乙酰紫杉醇为原料转化生产多烯紫杉醇的方法 | |
CN103736099B (zh) | 硝基苯基烷酸与碱性抗肿瘤药物连接的前体药物及其制备方法 | |
CN107365282B (zh) | 一种10,13-二支链-紫杉醇的制备方法 | |
CN117567522A (zh) | 一种二茂铁-2,4-二硝基苯磺酰氯缀合物、制备方法和应用 | |
CN115746069B (zh) | 一种x射线响应激活释放药物分子的化合物及其合成方法 | |
CN110279871A (zh) | 一种具有pH响应性的β-环糊精-阿霉素前药分子及其制备方法 | |
CN108383765A (zh) | 苯丁酸氮芥-多巴胺缀合物的合成及前药纳米粒子的制备 | |
CN113209131A (zh) | 一种有机-无机双药杂化抗肿瘤分子、制备方法及其应用 | |
RO111677B1 (ro) | Procedeu si intermediar pentru prepararea oxitetraciclinei pure | |
CN116715706B (zh) | 一种延长茶氨酸体内半衰期的化学修饰方法 | |
CN114621985B (zh) | 一种生物催化合成紫杉醇侧链的方法 | |
CN114621986B (zh) | 一种生物合成紫杉醇侧链的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230913 Address after: 518000 1104, Building A, Zhiyun Industrial Park, No. 13, Huaxing Road, Henglang Community, Longhua District, Shenzhen, Guangdong Province Applicant after: Shenzhen Hongyue Information Technology Co.,Ltd. Address before: 710021 Shaanxi province Xi'an Weiyang University Park Applicant before: SHAANXI University OF SCIENCE & TECHNOLOGY |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231107 Address after: 21-8, Building 1, No. 48 Tenglong Avenue, Tushan Town, Nan'an District, Chongqing, 400000 Applicant after: Fu Xunzhong Address before: 518000 1104, Building A, Zhiyun Industrial Park, No. 13, Huaxing Road, Henglang Community, Longhua District, Shenzhen, Guangdong Province Applicant before: Shenzhen Hongyue Information Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231218 Address after: 610000 Tianfu International Biological City, Chengdu, Sichuan Province (No. 501, Building 4, No. 8 Huigu Road, Shuangliu District) Patentee after: Chengdu Yaoyilikang Pharmaceutical Technology Co.,Ltd. Address before: 21-8, Building 1, No. 48 Tenglong Avenue, Tushan Town, Nan'an District, Chongqing, 400000 Patentee before: Fu Xunzhong |